Boston Scientific invests $1.5 billion in MiRus for TAVR expansion
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Subscribe To Our Newsletter & Stay Updated